Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor (original) (raw)

References

1. Engelman, J.A., Luo, J. & Cantley, L.C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 7, 606–619 (2006).
   Google Scholar
2. Manning, B.D. & Cantley, L.C. AKT/PKB signaling: navigating downstream. Cell 129, 1261–1274 (2007).
   Google Scholar
3. Samuels, Y. & Ericson, K. Oncogenic PI3K and its role in cancer. Curr. Opin. Oncol. 18, 77–82 (2006).
   Google Scholar
4. Martelli, A.M. et al. Involvement of the phosphoinositide 3-kinase/Akt signaling pathway in the resistance to therapeutic treatments of human leukemias. Histol. Histopathol. 20, 239–252 (2005).
   Google Scholar
5. Wee, S. et al. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res. 69, 4286–4293 (2009).
   Google Scholar
6. Yap, T.A. et al. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls and promises. Curr. Opin. Pharmacol. 8, 393–412 (2008).
   Google Scholar
7. Abraham, R.T. Regulation of the mTOR signaling pathway: from laboratory bench to bedside and back again. F1000 Biology Reports 1, 8 (2009).
   Google Scholar
8. Guertin, D.A. & Sabatini, D.M. Defining the role of mTOR in cancer. Cancer Cell 12, 9–22 (2007).
   Google Scholar
9. Abraham, R.T. & Eng, C.H. Mammalian target of rapamycin as a therapeutic target in oncology. Expert Opin. Ther. Targets 12, 209–222 (2008).
   Google Scholar
10. Guertin, D.A. & Sabatini, D.M. The pharmacology of mTOR inhibition. Sci. Signal. 2, pe24 (2009).
    Google Scholar
11. Janes, M.R. & Fruman, D.A. Immune regulation by rapamycin: moving beyond T cells. Sci. Signal. 2, pe25 (2009).
    Google Scholar
12. Thomson, A.W., Turnquist, H.R. & Raimondi, G. Immunoregulatory functions of mTOR inhibition. Nat. Rev. Immunol. 9, 324–337 (2009).
    Google Scholar
13. Choo, A.Y., Yoon, S.O., Kim, S.G., Roux, P.P. & Blenis, J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc. Natl. Acad. Sci. USA 105, 17414–17419 (2008).
    Google Scholar
14. Feldman, M.E. et al. Active-Site Inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 7, e38 (2009).
    Google Scholar
15. García-Martínez, J.M. et al. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem. J. 421, 29–42 (2009).
    Google Scholar
16. Thoreen, C.C. et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem. 284, 8023–8032 (2009).
    Google Scholar
17. Yu, K. et al. Biochemical, cellular and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res. 69, 6232–6240 (2009).
    Google Scholar
18. Chiarini, F. et al. Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia. Cancer Res. 69, 3520–3528 (2009).
    Google Scholar
19. Kharas, M.G. et al. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. J. Clin. Invest. 118, 3038–3050 (2008).
    Google Scholar
20. Kojima, K., et al. The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML. Leukemia 22, 1728–1736 (2008).
    Google Scholar
21. Park, S. et al. PI-103, a dual inhibitor of class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. Leukemia 22, 1698–1706 (2008).
    Google Scholar
22. Burgess, M.R. & Sawyers, C.L. Treating imatinib-resistant leukemia: the next generation targeted therapies. ScientificWorldJournal 6, 918–930 (2006).
    Google Scholar
23. Druker, B.J. Translation of the Philadelphia chromosome into therapy for CML. Blood 112, 4808–4817 (2008).
    Google Scholar
24. Li, S., Ilaria, R.L. Jr., Million, R.P., Daley, G.Q. & Van Etten, R.A. The P190, P210 and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J. Exp. Med. 189, 1399–1412 (1999).
    Google Scholar
25. Raynaud, F.I. et al. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res. 67, 5840–5850 (2007).
    Google Scholar
26. Maira, S.M. et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 7, 1851–1863 (2008).
    Google Scholar
27. Gruber, F., Mustjoki, S. & Porkka, K. Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome–positive acute lymphoblastic leukaemia. Br. J. Haematol. 145, 581–597 (2009).
    Google Scholar
28. Talpaz, M. et al. Dasatinib in imatinib-resistant Philadelphia chromosome–positive leukemias. N. Engl. J. Med. 354, 2531–2541 (2006).
    Google Scholar
29. Hu, Y. et al. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc. Natl. Acad. Sci. USA 103, 16870–16875 (2006).
    Google Scholar
30. McCubrey, J.A. et al. Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia 22, 708–722 (2008).
    Google Scholar
31. Foa, R. et al. Line treatment of adult Ph+ acute lymphoblastic leukemia (ALL) patients. Final results of the GIMEMA LAL1205 study. Blood 112, abstract 305 (2008).
    Google Scholar
32. Prabhu, S. et al. A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation. Oncogene 26, 1188–1200 (2007).
    Google Scholar
33. Zhang, M. et al. Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance. Mol. Cell. Biol. 28, 6496–6509 (2008).
    Google Scholar
34. Hedrick, S.M. The cunning little vixen: Foxo and the cycle of life and death. Nat. Immunol. 10, 1057–1063 (2009).
    Google Scholar
35. Huang, H. & Tindall, D.J. Dynamic FoxO transcription factors. J. Cell Sci. 120, 2479–2487 (2007).
    Google Scholar
36. Copp, J., Manning, G. & Hunter, T. TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2. Cancer Res. 69, 1821–1827 (2009).
    Google Scholar
37. García-Martínez, J.M. & Alessi, D.R. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochem. J. 416, 375–385 (2008).
    Google Scholar
38. Kennedy, J.A. & Barabe, F. Investigating human leukemogenesis: from cell lines to in vivo models of human leukemia. Leukemia 22, 2029–2040 (2008).
    Google Scholar
39. Sarbassov, D.D. et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22, 159–168 (2006).
    Google Scholar
40. Mohi, M.G. et al. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc. Natl. Acad. Sci. USA 101, 3130–3135 (2004).
    Google Scholar
41. Luo, F.R. et al. Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure. Clin. Cancer Res. 12, 7180–7186 (2006).
    Google Scholar
42. Sankhala, K. et al. The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents. Target. Oncol. 4, 135–142 (2009).
    Google Scholar
43. Durand, C.A. et al. Phosphoinositide 3-kinase p110δ regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses. J. Immunol. 183, 5673–5684 (2009).
    Google Scholar
44. Delgoffe, G.M. et al. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 30, 832–844 (2009).
    Google Scholar
45. Sharma, S.V., Fischbach, M.A., Haber, D.A. & Settleman, J. 'Oncogenic shock': explaining oncogene addiction through differential signal attenuation. Clin. Cancer Res. 12, 4392s–4395s (2006).
    Google Scholar
46. Shor, B., Cavender, D. & Harris, C. A kinase-dead knock-in mutation in mTOR leads to early embryonic lethality and is dispensable for the immune system in heterozygous mice. BMC Immunol. 10, 28 (2009).
    Google Scholar
47. Fruman, D.A. & Bismuth, G. Fine tuning the immune response with PI3K. Immunol. Rev. 228, 253–272 (2009).
    Google Scholar
48. Lopez-Fauqued, M., et al. The dual PI3K/mTOR inhibitor (PI-103) promotes immunosupression, in vivo tumor growth and increases survival of sorafenib treated melanoma cells. Int. J. Cancer published online, doi:10.1002/ijc.24926 (6 October 2009).
49. Apsel, B. et al. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat. Chem. Biol. 4, 691–699 (2008).
    Google Scholar

Download references